Morgan Stanley Reiterates Overweight on SH PHARMA (02607), Trims Target Price to HK$15.8

Stock News04-24

Morgan Stanley has released a research report reiterating its "Overweight" rating on SH PHARMA (02607), while reducing the target price from HK$16 to HK$15.8, a decrease of 1.25%. The firm stated that following SH PHARMA's 2025 results announcement, it has lowered its profit forecasts for the company for the years 2026 to 2030 by 2% to 3%, reflecting a lower revenue outlook. The bank also indicated that the better-than-expected performance of SH PHARMA's distribution business is a key factor supporting the "Overweight" rating. It projects the company's overall profit to achieve a compound annual growth rate of 9% from 2025 to 2028, with a forecasted price-to-earnings ratio of approximately 7 times for 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170029595?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170029595","market":"fut","top_or_hot":-1,"title":"Morgan Stanley Reiterates Overweight on SH PHARMA (02607), Trims Target Price to HK$15.8","media":"Stock News","content":"<p>Morgan Stanley has released a research report reiterating its \"Overweight\" rating on SH PHARMA (02607), while reducing the target price from HK$16 to HK$15.8, a decrease of 1.25%. The firm stated that following SH PHARMA's 2025 results announcement, it has lowered its profit forecasts for the company for the years 2026 to 2030 by 2% to 3%, reflecting a lower revenue outlook. The bank also indicated that the better-than-expected performance of SH PHARMA's distribution business is a key factor supporting the \"Overweight\" rating. It projects the company's overall profit to achieve a compound annual growth rate of 9% from 2025 to 2028, with a forecasted price-to-earnings ratio of approximately 7 times for 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley Reiterates Overweight on SH PHARMA (02607), Trims Target Price to HK$15.8</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley Reiterates Overweight on SH PHARMA (02607), Trims Target Price to HK$15.8\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-24 17:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Morgan Stanley has released a research report reiterating its \"Overweight\" rating on SH PHARMA (02607), while reducing the target price from HK$16 to HK$15.8, a decrease of 1.25%. The firm stated that following SH PHARMA's 2025 results announcement, it has lowered its profit forecasts for the company for the years 2026 to 2030 by 2% to 3%, reflecting a lower revenue outlook. The bank also indicated that the better-than-expected performance of SH PHARMA's distribution business is a key factor supporting the \"Overweight\" rating. It projects the company's overall profit to achieve a compound annual growth rate of 9% from 2025 to 2028, with a forecasted price-to-earnings ratio of approximately 7 times for 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"601607","symbol_name":"上海医药","start_time":0,"source_url":"","article_id":"1170029595","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170029595","pubTimestamp":1777021852,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Morgan Stanley has released a research report reiterating its \"Overweight\" rating on SH PHARMA (02607), while reducing the target price from HK$16 to HK$15.8, a decrease of 1.25%. The firm stated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0175":"白马股","BK0196":"行业龙头","BK0187":"一线龙头","EWH":"香港ETF-iShares MSCI","BK0184":"上海国资改革","BK0028":"国家队","BK0097":"医药电商","BK0099":"上海本地重组","BK0020":"浦东新区","02607":"上海医药","BK1197":"保健护理产品经销商","BK0183":"MSCI概念","BK0209":"零售","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"大摩重申跑赢大盘上海医药(02607)目标价下调至15.8港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"EWH":1,"02607":1},"content_text":"Morgan Stanley has released a research report reiterating its \"Overweight\" rating on SH PHARMA (02607), while reducing the target price from HK$16 to HK$15.8, a decrease of 1.25%. The firm stated that following SH PHARMA's 2025 results announcement, it has lowered its profit forecasts for the company for the years 2026 to 2030 by 2% to 3%, reflecting a lower revenue outlook. The bank also indicated that the better-than-expected performance of SH PHARMA's distribution business is a key factor supporting the \"Overweight\" rating. It projects the company's overall profit to achieve a compound annual growth rate of 9% from 2025 to 2028, with a forecasted price-to-earnings ratio of approximately 7 times for 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170029595","isCrawlerRequest":true}